Coming together at the hinges: Therapeutic prospects of IgG3
Open Access
- 1 January 2021
- journal article
- review article
- Published by Taylor & Francis Ltd in mAbs
- Vol. 13 (1), 1882028
- https://doi.org/10.1080/19420862.2021.1882028
Abstract
The human IgG3 subclass is conspicuously absent among the formats for approved monoclonal antibody therapies and Fc fusion protein biologics. Concern about the potential for rapid degradation, reduced plasma half-life, and increased immunogenicity due to marked variation in allotypes has apparently outweighed the potential advantages of IgG3, which include high affinity for activating Fcγ receptors, effective complement fixation, and a long hinge that appears better suited for low abundance targets. This review aims to highlight distinguishing features of IgG3 and to explore its functional role in the immune response. We present studies of natural immunity and recombinant antibody therapies that elucidate key contributions of IgG3 and discuss historical roadblocks that no longer remain clearly relevant. Collectively, this body of evidence motivates thoughtful reconsideration of the clinical advancement of this distinctive antibody subclass for treatment of human diseases. Abbreviations: ADCC - Antibody-Dependent Cell-mediated CytotoxicityADE – Antibody-dependent enhancementAID – Activation-Induced Cytidine DeaminaseCH – Constant HeavyCHF – Complement factor HCSR – Class Switch RecombinationEM - Electron MicroscopyFab – Fragment, antigen bindingFc – Fragment, crystallizableFcRn – Neonatal Fc ReceptorFcγR – Fc gamma ReceptorHIV – Human Immunodeficiency VirusIg - ImmunoglobulinIgH – Immunoglobulin Heavy chain geneNHP – Non-Human PrimateKeywords
Funding Information
- This work was supported by the National Institutes of Health NIAID and NIGMS (R01AI131975)
- National Institutes of Health (P01AI120756)
- National Institutes of Health (R01AI131975)
This publication has 176 references indexed in Scilit:
- Human IgG Subclasses against Enterovirus Type 71: Neutralization versus Antibody Dependent Enhancement of InfectionPLOS ONE, 2013
- Effects of age on H1N1-specific serum IgG1 and IgG3 levels evaluated during the 2011–2012 influenza vaccine seasonImmunity & Ageing, 2013
- Early Appearance of Neutralizing Immunoglobulin G3 Antibodies Is Associated With Chikungunya Virus Clearance and Long-term Clinical ProtectionThe Journal of Infectious Diseases, 2012
- Multiple HIV-1-specific IgG3 responses decline during acute HIV-1AIDS, 2011
- Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potentialNature Communications, 2011
- Human IgG isotypes and activating Fcγ receptors in the interaction of Salmonella enterica serovar Typhimurium with phagocytic cellsImmunology, 2011
- Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q bindingProtein Science, 2010
- Human IgG2 Antibody Disulfide Rearrangement in VivoOnline Journal of Public Health Informatics, 2008
- Human IgG2 Antibodies Display Disulfide-mediated Structural IsoformsOnline Journal of Public Health Informatics, 2008
- Stable antibody expression at therapeutic levels using the 2A peptideNature Biotechnology, 2005